TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fluoxetine for Motor Recovery After Acute Intracerebral Hemorrhage (FMRICH): a Randomised Placebo-controlled Trial
Brief Summary: This is a randomized, double-blind, placebo-controlled, multicenter clinical trial that will be carried out in Mexico. The purpose of this study is to test whether a 3-month treatment with fluoxetine enhances motor recovery in non-depressed patients with acute intracerebral hemorrhage.


Options:
A: Arm Label: SSRI; Type: EXPERIMENTAL; Interventions: Drug: SSRI | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SSRI; Assigned to Arm(s): SSRI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1 Problem Solving Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Therapy | Arm Label: 2. Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: 3 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): 1 Problem Solving Therapy | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): 2. Escitalopram | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3 Placebo
D: Arm Label: escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: sugar pill | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): escitalopram | Intervention Type: DRUG; Name: sugar pill; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Two-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-Controlled Study of Safety and Efficacy of Microporous, Fractionated, Protonated Zirconium Silicate in Mild to Moderate Hyperkalemia
Brief Summary: Acute Phase: It is hypothesized that ZS (zirconium silicate) is more effective than placebo control (alternative hypothesis) in lowering S-K levels in subjects with S-K between 5.0 - 6.5 mmol/l versus no difference between ZS and placebo control (null hypothesis).

Subacute Phase (randomized withdrawal): It is hypothesized that ZS once daily is more effective than placebo control (alternative hypotheses) in maintaining normokalemic levels (3.5 - 4.9 mmol/l) among subjects completing the Acute Phase versus no difference between each ZS dose and respective placebo controls (null hypotheses).


Options:
A: Arm Label: Sodium Zirconium Cyclosilicate (ZS); Type: EXPERIMENTAL; Interventions: Drug: Sodium Zirconium Cyclosilicate (ZS) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sodium Zirconium Cyclosilicate (ZS); Assigned to Arm(s): Sodium Zirconium Cyclosilicate (ZS)
B: Arm Label: Group 1 - Patiromer; Type: EXPERIMENTAL; Interventions: Drug: Patiromer, Drug: Spironolactone | Arm Label: Group 2 - Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Spironolactone | Intervention Type: DRUG; Name: Patiromer; Assigned to Arm(s): Group 1 - Patiromer | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2 - Placebo | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Group 1 - Patiromer, Group 2 - Placebo
C: Arm Label: Zirconium silicate (acute phase); Type: EXPERIMENTAL; Interventions: Drug: Zirconium silicate (acute phase) | Arm Label: Placebo (acute phase); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (acute phase) | Arm Label: Zirconium silicate (subacute phase); Type: EXPERIMENTAL; Interventions: Drug: Zirconium silicate (subacute phase) | Arm Label: Placebo (subacute phase); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo ( subacute phase) | Intervention Type: DRUG; Name: Zirconium silicate (acute phase); Assigned to Arm(s): Zirconium silicate (acute phase) | Intervention Type: DRUG; Name: Zirconium silicate (subacute phase); Assigned to Arm(s): Zirconium silicate (subacute phase) | Intervention Type: DRUG; Name: Placebo (acute phase); Assigned to Arm(s): Placebo (acute phase) | Intervention Type: DRUG; Name: Placebo ( subacute phase); Assigned to Arm(s): Placebo (subacute phase)
D: Arm Label: Group 1 - Dosing Without Food; Type: EXPERIMENTAL; Interventions: Drug: patiromer | Arm Label: Group 2 - Dosing With Food; Type: ACTIVE_COMPARATOR; Interventions: Drug: patiromer | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Group 1 - Dosing Without Food, Group 2 - Dosing With Food

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2
Brief Summary: This study is being done to find out if an investigational product called HP802-247 can help people with venous leg ulcers. Investigational means that HP802-247 has not been approved by the U.S. Food and Drug Administration (FDA).

At least 250 subjects will participate. The study is going to be conducted in approximately 50 sites in the United States and Canada.


Options:
A: Arm Label: HP802-247; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Biological: Vehicle | Intervention Type: BIOLOGICAL; Name: HP802-247; Assigned to Arm(s): HP802-247 | Intervention Type: BIOLOGICAL; Name: Vehicle; Assigned to Arm(s): Vehicle
B: Arm Label: HP802-247 plus compression therapy; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: HP802-247 Vehicle plus compression therapy; Type: PLACEBO_COMPARATOR; Interventions: Other: HP802-247 Vehicle | Intervention Type: BIOLOGICAL; Name: HP802-247; Assigned to Arm(s): HP802-247 plus compression therapy | Intervention Type: OTHER; Name: HP802-247 Vehicle; Assigned to Arm(s): HP802-247 Vehicle plus compression therapy
C: Arm Label: HP802-247; Type: EXPERIMENTAL; Interventions: Biological: HP-802-247 | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Biological: Vehicle | Intervention Type: BIOLOGICAL; Name: HP-802-247; Assigned to Arm(s): HP802-247 | Intervention Type: BIOLOGICAL; Name: Vehicle; Assigned to Arm(s): Vehicle
D: Arm Label: A - Low Q7D; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: B - Low Q14D; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: C - High Q7D; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: D - High Q14D; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: E - Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo (Vehicle) | Intervention Type: BIOLOGICAL; Name: HP802-247; Assigned to Arm(s): A - Low Q7D, B - Low Q14D, C - High Q7D, D - High Q14D | Intervention Type: BIOLOGICAL; Name: Placebo (Vehicle); Assigned to Arm(s): E - Vehicle

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lactobacillus Reuteri Reduces Pulmonary Exacerbations and Upper Respiratory Tract Infections in CF Patients With Mild-to-moderate Lung Disease. LR Administration Might Have a Beneficial Effect on the Disease Course of Cystic Fibrosis.
Brief Summary: The purpose of this study is to evaluate in patients with cystic fibrosis the effect of Lactobacillus Reuteri (LR) on the rate of respiratory exacerbations and of the infections of both upper respiratory and gastrointestinal tracts.


Options:
A: Arm Label: Bifidobacterium animalis subsp. lactis; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium animalis subsp. lactis | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium animalis subsp. lactis; Assigned to Arm(s): Bifidobacterium animalis subsp. lactis
B: Arm Label: Lactobacillus reuteri (LR) ATCC55730; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus reuteri | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus reuteri; Assigned to Arm(s): Lactobacillus reuteri (LR) ATCC55730 | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Modified formula (MFGM-enriched formula with reduced energy and protein content) | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Modified formula (MFGM-enriched formula with reduced energy and protein content); Assigned to Arm(s): 1
D: Arm Label: Cow's Milk; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cow's milk | Arm Label: Follow-On Formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Follow-On Formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Cow's milk; Assigned to Arm(s): Cow's Milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Follow-On Formula; Assigned to Arm(s): Follow-On Formula

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Interventional Treatment, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon in Primary IgA Nephropathy Patients at Risk of End-stage Renal Disease
Brief Summary: The objective of the study is to evaluate efficacy and safety of two different doses of NEFECON in the treatment of patients with primary IgA nephropathy (IgAN) at risk of developing end-stage renal disease, under rigorous blood pressure control with an angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin II receptor I blocker (ARB).


Options:
A: Arm Label: Tacrolimus group; Type: EXPERIMENTAL; Interventions: Drug: Tacrolimus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): Tacrolimus group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: NEFECON 8 mg/day; Type: EXPERIMENTAL; Interventions: Drug: NEFECON | Arm Label: NEFECON 16 mg/day; Type: EXPERIMENTAL; Interventions: Drug: NEFECON | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: NEFECON; Assigned to Arm(s): NEFECON 16 mg/day, NEFECON 8 mg/day | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: supportive therapy with: ACE-inhibitor / ARB / Statin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: supportive and immunosuppressive therapy | Intervention Type: DRUG; Name: supportive therapy with: ACE-inhibitor / ARB / Statin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: supportive and immunosuppressive therapy; Assigned to Arm(s): B
D: Intervention Type: DRUG; Name: prednisone + Inhibace/Cozaar; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Inhibace/Cozaar; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Applicability and Efficiency of Different Approaches in Lifestyle Interventions - Lifestyle Management and Changes in Everyday Life
Brief Summary: The purpose of this study is to examine the effectiveness and applicability of different interventions designed for enhancing overall wellbeing. Lifestyle changes, as well as psychological and physiological health variables are assessed. The interventions are based on the principles of cognitive behavioural therapy, and delivered either face-to-face, via mobile phone application, or Internet.


Options:
A: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Use of PDA + support to reduce weight and pain | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: MOVE! level 2 group weight loss counseling | Intervention Type: BEHAVIORAL; Name: Use of PDA + support to reduce weight and pain; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: MOVE! level 2 group weight loss counseling; Assigned to Arm(s): Arm 2
B: Arm Label: Noom Health; Type: EXPERIMENTAL; Interventions: Behavioral: Noom Health | Arm Label: Noom Digital Health; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Noom Digital Health | Intervention Type: BEHAVIORAL; Name: Noom Health; Assigned to Arm(s): Noom Health | Intervention Type: BEHAVIORAL; Name: Noom Digital Health; Assigned to Arm(s): Noom Digital Health
C: Arm Label: Smartphone App Participants (APP); Type: EXPERIMENTAL; Interventions: Behavioral: Smartphone App Participants (APP) | Arm Label: Diabetes Prevention Program Participants (DPP); Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Prevention Program Participants (DPP) | Intervention Type: BEHAVIORAL; Name: Smartphone App Participants (APP); Assigned to Arm(s): Smartphone App Participants (APP) | Intervention Type: BEHAVIORAL; Name: Diabetes Prevention Program Participants (DPP); Assigned to Arm(s): Diabetes Prevention Program Participants (DPP)
D: Arm Label: Face-to-Face; Type: EXPERIMENTAL; Interventions: Behavioral: Wellbeing intervention (ACT) | Arm Label: Mobile; Type: EXPERIMENTAL; Interventions: Behavioral: Wellbeing intervention (ACT) | Arm Label: Internet; Type: EXPERIMENTAL; Interventions: Behavioral: Wellbeing intervention (Internet) | Arm Label: Control; Type: EXPERIMENTAL; Interventions: Behavioral: No intervention | Intervention Type: BEHAVIORAL; Name: Wellbeing intervention (ACT); Assigned to Arm(s): Face-to-Face, Mobile | Intervention Type: BEHAVIORAL; Name: Wellbeing intervention (Internet); Assigned to Arm(s): Internet | Intervention Type: BEHAVIORAL; Name: No intervention; Assigned to Arm(s): Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Applicability and Efficiency of Different Approaches in Lifestyle Interventions - Lifestyle Management and Changes in Everyday Life
Brief Summary: The purpose of this study is to examine the effectiveness and applicability of different interventions designed for enhancing overall wellbeing. Lifestyle changes, as well as psychological and physiological health variables are assessed. The interventions are based on the principles of cognitive behavioural therapy, and delivered either face-to-face, via mobile phone application, or Internet.


Options:
A: Arm Label: MBCT; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-Based Cognitive Therapy (MBCT) | Arm Label: CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy (CBT) | Arm Label: Waitlist; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness-Based Cognitive Therapy (MBCT); Assigned to Arm(s): MBCT | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): CBT
B: Arm Label: Face-to-Face; Type: EXPERIMENTAL; Interventions: Behavioral: Wellbeing intervention (ACT) | Arm Label: Mobile; Type: EXPERIMENTAL; Interventions: Behavioral: Wellbeing intervention (ACT) | Arm Label: Internet; Type: EXPERIMENTAL; Interventions: Behavioral: Wellbeing intervention (Internet) | Arm Label: Control; Type: EXPERIMENTAL; Interventions: Behavioral: No intervention | Intervention Type: BEHAVIORAL; Name: Wellbeing intervention (ACT); Assigned to Arm(s): Face-to-Face, Mobile | Intervention Type: BEHAVIORAL; Name: Wellbeing intervention (Internet); Assigned to Arm(s): Internet | Intervention Type: BEHAVIORAL; Name: No intervention; Assigned to Arm(s): Control
C: Arm Label: ACT-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: ACT-based intervention, Behavioral: usual care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: ACT-based intervention; Assigned to Arm(s): ACT-based intervention | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): ACT-based intervention, Usual care
D: Arm Label: Cardiac Rehabilitation plus Transcendental Meditation; Type: EXPERIMENTAL; Interventions: Behavioral: Cardiac Rehabilitation plus Transcendental Meditation | Arm Label: Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation plus Transcendental Meditation | Intervention Type: BEHAVIORAL; Name: Cardiac Rehabilitation plus Transcendental Meditation; Assigned to Arm(s): Cardiac Rehabilitation, Cardiac Rehabilitation plus Transcendental Meditation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sustained Inflations to Achieve Lung Aeration at Birth - a Randomized Control Trial
Brief Summary: To determine if respiratory support at birth guided by RFM decreases BPD.


Options:
A: Arm Label: Intervention (CC+SI); Type: EXPERIMENTAL; Interventions: Procedure: CC+SI | Arm Label: Control (3:1 C:V); Type: ACTIVE_COMPARATOR; Interventions: Procedure: 3:1 C:V | Intervention Type: PROCEDURE; Name: CC+SI; Assigned to Arm(s): Intervention (CC+SI) | Intervention Type: PROCEDURE; Name: 3:1 C:V; Assigned to Arm(s): Control (3:1 C:V)
B: Arm Label: Control Arm-Standard of care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard of Care | Arm Label: Sustained Intervention; Type: EXPERIMENTAL; Interventions: Procedure: Sustained Inflation | Intervention Type: PROCEDURE; Name: Sustained Inflation; Assigned to Arm(s): Sustained Intervention | Intervention Type: PROCEDURE; Name: Standard of Care; Assigned to Arm(s): Control Arm-Standard of care
C: Arm Label: "SI group"; Type: EXPERIMENTAL; Interventions: Procedure: SI group | Arm Label: IPPV group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "IPPV group" | Intervention Type: PROCEDURE; Name: "IPPV group"; Assigned to Arm(s): IPPV group | Intervention Type: PROCEDURE; Name: SI group; Assigned to Arm(s): "SI group"
D: Arm Label: SI+CC; Type: EXPERIMENTAL; Interventions: Procedure: CC+SI | Arm Label: 3:1 CPR; Type: ACTIVE_COMPARATOR; Interventions: Procedure: 3:1 CPR | Intervention Type: PROCEDURE; Name: CC+SI; Assigned to Arm(s): SI+CC | Intervention Type: PROCEDURE; Name: 3:1 CPR; Assigned to Arm(s): 3:1 CPR

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-Label, Phase II Study Assessing the Efficacy and the Safety of Bevacizumab in Neoadjuvant Therapy in Patients With FIGO Stage IIIC/IV Ovarian, Tubal or Peritoneal Adenocarcinoma, Initially Unresectable
Brief Summary: This randomized, open-label study will evaluate the efficacy and safety of neoadjuvant bevacizumab in participants with initially unresectable, FIGO stage IIIC/IV ovarian, tubal, or peritoneal cancer. Participants will be randomized to receive 8 cycles of carboplatin plus paclitaxel with or without bevacizumab before surgery (interval debulking surgery \[IDS\]). Surgery will be scheduled 28 days after the last course of neoadjuvant treatment in participants with resectable cancer. Participants with unresectable cancer will go through the follow-up period. All participants will receive bevacizumab for Cycles 6 to 26.


Options:
A: Arm Label: Carboplatin + Paclitaxel + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Bevacizumab | Arm Label: Carboplatin + Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Bevacizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Carboplatin + Paclitaxel, Carboplatin + Paclitaxel + Bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Carboplatin + Paclitaxel, Carboplatin + Paclitaxel + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Carboplatin + Paclitaxel, Carboplatin + Paclitaxel + Bevacizumab
B: Arm Label: Arm 1: Niraparib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Niraparib | Arm Label: Arm 2: Niraparib and Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Niraparib | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm 2: Niraparib and Bevacizumab | Intervention Type: DRUG; Name: Niraparib; Assigned to Arm(s): Arm 1: Niraparib, Arm 2: Niraparib and Bevacizumab
C: Arm Label: gemcitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine | Arm Label: Gemcitabine + pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine, Drug: pazopanib | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine + pazopanib, gemcitabine | Intervention Type: DRUG; Name: pazopanib; Assigned to Arm(s): Gemcitabine + pazopanib
D: Arm Label: DOXIL + trabectedin; Type: EXPERIMENTAL; Interventions: Drug: Trabectedin, Drug: DOXIL, Drug: Dexamethasone | Arm Label: DOXIL; Type: ACTIVE_COMPARATOR; Interventions: Drug: DOXIL | Intervention Type: DRUG; Name: Trabectedin; Assigned to Arm(s): DOXIL + trabectedin | Intervention Type: DRUG; Name: DOXIL; Assigned to Arm(s): DOXIL, DOXIL + trabectedin | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): DOXIL + trabectedin

Answer: A